Beta Bionics (BBNX) vs Bioventus (BVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bioventus (BVS) has outperformed Beta Bionics (BBNX) over the past year, gaining 36.5% versus a loss of 57.5%. Beta Bionics is the larger company by market cap ($726.3 million vs $676.5 million), about 1.1 times the size. Bioventus converts more of its revenue into profit, with a net margin of 4.0% versus -73.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBNX | BVS |
|---|---|---|
| Share price | $13.36 | $9.88 |
| Market cap | $726.34M | $676.53M |
| 1-day change | +0.30% | -0.70% |
| YTD return | -56.15% | +32.80% |
| 1-year return | -57.48% | +36.46% |
| 5-year return | — | -21.02% |
| P/E ratio (TTM) | — | 12.20 |
| Forward P/E | — | 11.13 |
| EPS (TTM) | $-1.83 | $0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $100.25M | $568.09M |
| Revenue growth (YoY) | +53.94% | -0.91% |
| Net income (latest FY) | $-73.20M | $22.73M |
| Gross margin | 55.40% | 68.33% |
| Operating margin | -71.50% | 9.50% |
| Net margin | -73.02% | 4.00% |
| 52-week high | $32.71 | $15.89 |
| 52-week low | $8.80 | $7.02 |
| Distance from 52-week high | -59.16% | -37.83% |
| Analyst consensus | buy | none |
| Avg. price target upside | +87.87% | +68.02% |
| Average volume | 1.21M | 536.81K |
| Shares outstanding | 54.37M | 68.47M |
| Employees | 420 | 960 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BVS has outperformed BBNX by 93.9 percentage points over the past year.
- Bioventus is more profitable, keeping 4.0 cents of every revenue dollar as net income versus -73.0 cents for Beta Bionics.
- Beta Bionics grew revenue faster in its latest fiscal year (+53.94% vs -0.91%).
About Beta Bionics
BBNX stock →Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Health Care · Medical/Dental Instruments · 420 employees
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Health Care · Medical/Dental Instruments · 960 employees
BBNX vs BVS FAQ
Which is bigger, Beta Bionics or Bioventus?
Beta Bionics (BBNX) is larger, with a market capitalization of $726.34M compared with $676.53M for Bioventus (BVS).
Which stock has performed better over the past year, BBNX or BVS?
BVS returned +36.46% over the past 12 months, compared with -57.48% for BBNX (price return, excluding dividends). Past performance does not predict future results.
Are Beta Bionics and Bioventus in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.